Health Canada
Symbol of the Government of Canada
Consumer Product Safety

Incident Report

Subform I: General Information

1. Report Type.

New incident report

Incident Report Number: 2021-2987

2. Registrant Information.

Registrant Reference Number: M-754195-01-1

Registrant Name (Full Legal Name no abbreviations): Bayer CropScience Inc.

Address: Suite 200, 160 Quarry Park Blvd S.E.

City: Calgary

Prov / State: Alberta

Country: Canada

Postal Code: T2C 3G3

3. Select the appropriate subform(s) for the incident.

Scientific Study

4. Date registrant was first informed of the incident.

5. Location of incident.

6. Date incident was first observed.

Product Description

7. a) Provide the active ingredient and, if available, the registration number and product name (include all tank mixes). If the product is not registered provide a submission number.


PMRA Registration No. 28952      PMRA Submission No.       EPA Registration No.


  • Active Ingredient(s)
      • Guarantee/concentration 97.82 %

7. b) Type of formulation.

Application Information

8. Product was applied?


9. Application Rate.

10. Site pesticide was applied to (select all that apply).

11. Provide any additional information regarding application (how it was applied, amount applied, the size of the area treated etc).

To be determined by Registrant

12. In your opinion, was the product used according to the label instructions?


Subform VII: Scientific Study

1. Study Reference

Title Spirotetramat Cis-enol BCS-AR12397: Chronic Oral Toxicity Test on the Honey Bee (Apis mellifera L.) in the Laboratory

Date 29-SEP-20

2. a) Is an extension needed to translate the document?


3. Type of incident identified in the study

New health or environmental hazard

4. Describe the incident identified in the study (e.g. study demonstrates an increased risk to non-Hodgkin's Lymphoma after exposure to pesticide X)

A study was conducted with the metabolite spirotetramat-cis-enol (technical compound). This study describes the chronic oral toxicity of spirotetramat-cis-enol to honey bees. There is no previous endpoint for chronic oral exposure to honey bees with spirotetramat-cis-enol. The endpoint was found to be 10X lower than the current acute endpoint for the spirotetramat-cis-enol.

5. a) Was the study discontinued before completion?


5. b) Provide the reason for discontinuation

6. If the study is ongoing, what is the expected completion date?

For Registrant use only

7. Provide supplemental information here

The lower endpoint for spirotetramat-cis-enol does not change conclusions from the Tier I screening level (BeeREX), which identify potential risk to pollinators. Consequently, the refinements for toxicity with a Tier II colony feeding study and a series of residue (exposure) data still support the registered uses of spirotetramat.